Consistent with our findings, a previous study demonstrated that fenofibrate, a PPARα agonist, increased angiotensin II-independent CYP11B2 mRNA expression and aldosterone production in human adrenocortical carcinoma H295R cells, whereas a peroxisome proliferator-activated receptor-γ (PPARγ) agonist either had no effect or reduced aldosterone secretion [55]. The gene discussed is PPARG; the disease is adrenal cortex carcinoma.